Anagrelide

• Description :

  Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM) . Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Apoptosis; Phosphodiesterase (PDE)

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/anagrelide.html

• Purity :

  99.87

• Solubility :

  DMSO : 2.56 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C1NC2=NC3=C(C(Cl)=C(Cl)C=C3)CN2C1

• Molecular Formula :

  C10H7Cl2N3O

• Molecular Weight :

  256.09

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Guosu Wang, et al. Comparison of the biological activities of Anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol. 2005 Oct;146 (3) :324-32.|[2]Y Hong, et al. Comparison between Anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of Anagrelide for the megakaryocytic lineage. Leukemia. 2006 Jun;20 (6) :1117-22.|[3]Olli-Pekka Pulkka, et al. Anagrelide for Gastrointestinal Stromal Tumor. Clin Cancer Res. 2019 Mar 1;25 (5) :1676-1687.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [68475-42-3]